Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items: 2019-2024

Historic Non-cash Items for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $4.5 million.

  • 4D Molecular Therapeutics' Non-cash Items rose 45.40% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 45.40%. This contributed to the annual value of $4.5 million for FY2024, which is 45.02% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Non-cash Items stood at $4.5 million, which was up 45.02% from $3.1 million recorded in FY2023.
  • In the past 5 years, 4D Molecular Therapeutics' Non-cash Items registered a high of $24.7 million during FY2021, and its lowest value of $1.2 million during FY2020.
  • Its 3-year average for Non-cash Items is $3.4 million, with a median of $3.1 million in 2023.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Non-cash Items plummeted by 93.96% in 2020, and later skyrocketed by 1,942.91% in 2021.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Non-cash Items stood at $1.2 million in 2020, then surged by 1,942.91% to $24.7 million in 2021, then slumped by 90.35% to $2.4 million in 2022, then spiked by 31.46% to $3.1 million in 2023, then skyrocketed by 45.02% to $4.5 million in 2024.